Didn't I mention yesterday investors might start taking notice soon of Algae Dynamics Corp. (ADYNF)? Take a look at the chart so far on the day today. If this is any indication of what's to come, traders and investors might want to take a piece just to see where things go, because it appears the company may finally be starting to get some traction. Earlier this morning, the company announced a joint venture with ARA - Avanti Rx Analytics Inc. ("ARA") in a newly-formed subsidiary entity called ADC Biomedical Corp ("BIO"), the equity of which will be owned 4% and 96% by ARA and ADC, respectively. This comes on the heels of a previous announcement we brought to your attention back in March, whereby Algae Dynamics announced a memorandum of understanding with ARA with respect to strategic collaboration between the two companies. This announcement is an extension of that previously-announced collaboration. It is the intention of the joint venture for BIO to be the preferred purchaser from ARA of all BIO's and ADC's products containing algae, hemp oil, and cannabis extracted oils, and/or their compounds. ADC will be responsible for the provision of raw materials, or if required by law, will arrange for the provision of raw materials to ARA for processing. ARA will be responsible for processing the raw materials into finished bulk goods and/or packaged products, and shipping same to BIO's licensed clients/sellers and research organizations. ARA will process materials according to agreed prices and specifications, which may be modified from time to time. The initial term of the joint venture is for three (3) years, effective April 10, 2017, renewing automatically unless notice is given from one party to the other to terminate. In addition, the joint venture may be terminated upon the occurrence of a material breach that remains uncured for 60 days. Paul Ramsay, Chairman and President of the Company, said, "This joint venture positions the Company with the necessary channels to manufacture and sell BIO's and ADC's bulk and packaged products for sale, both domestically and export, as well as supply materials to support our research programs at University of Waterloo and Western University. ARA - Avanti Rx Analytics is the first and only independent Health Canada GMP and OCDS approved Contract Organization in the field of controlled drugs and substances particularly in the areas of medical marijuana, hemp, cannabinoids and marijuana-based concentrated products, which makes ARA an outstanding partner in our future endeavors." As reported earlier, the Company is continuing to seek opportunities to partner with or take ownership in existing Access to Cannabis for Medical Purposes Regulations (ACMPR) licensed producers to allow for access to the marketplace. Now here's why we think this news is so compelling today; if you're not familiar with Avanti Rx Analytics, they are the first Health Canada GMP and OCDS approved Contract Organization specializing in the field of controlled drugs and substances particularly in the areas of medicinal cannabis, hemp, cannabinoids, and cannabis based concentrated products. Additionally, Avanti Rx Analytics offers a comprehensive menu of services ranging from analytical R&D and QC testing, cannabis extraction under controlled environment, cannabinoids purification, cannabis infused-product formulation, and cannabis waste management by means of material denaturation, as well as the QA and regulatory consulting. See where this may potentially be going? If there's one thing I've learned when it comes to penny stocks is things often take time. They don't always pan out the way we think they might, but when they do look out - the results can be tremendous. And ADYNF's trading activity today is any indication of things to come, I think it's one small stock worth considering. Cannabis stocks are due to start heating up again, just make sure you're participating in the right ones - companies with the necessary financial backing and a promising model to go with it.